All News

Vaccinated individuals overall had large amounts of antibodies present compared to infected individuals, suggesting that vaccination both protects against becoming infected and reduces the likelihood of transmitting the virus to others.

Individuals with at least one inactive copy of the gene have lower BMIs and, on average, face a 54% lower risk of obesity than individuals without the mutations.

Pharmacists who are proactive—in other words, taking account of the environment and being able to foresee health systems and patients’ needs ahead of time—are more effective in promoting practice change.

The study analyzed nearly 4000 patients with these pathologies and 30,000 control individuals, examining the neurobiological basis for aggressive behavior.

In an interview with Pharmacy Times, Chris Zaleski, PharmD, RPh, said pharmacy technicians are essential pharmacy team members to prevent dispensing errors and enhance patient care.

Mary Reed, DrPH, research scientist at Kaiser Permanente, discussed the challenges encountered by health systems and patients during the shift to online care.

Pharmacy Times spoke with Bhavesh Shah, associate chief pharmacy officer for hematology/oncology, about his session titled Stand Strong Against Platelet Destruction With Tavalisse®: A Patient’s ITP Treatment Journey, which he presented at the 2021 ATOPP Summit.

Pharmacies that received more than $750,000 in federal funds, including funds from the CARES Act Provider Relief Fund, will be subject to single audit requirements.

Because viral clearance is compromised if HIV is allowed to replicate for an extended period of time—resulting in extensive damage to the immune system—controlling HIV with antiretroviral therapy may be critical to preventing this type of viral evolution in SARS-CoV-2 in patients with advanced HIV.

The researchers also tested the effectiveness of 2 different transmission control strategies.

Patients may consult with their pharmacist regarding appropriate protection methods and treatment options available for common summer skin ailments.

Despite the encouraging progression-free survival findings, data on overall survival resulted in a partial clinical hold instituted by the FDA.

The study plans to enroll approximately 180 participants to evaluate the safety, reactogenicity, and immunogenicity of its quadrivalent seasonal influenza mRNA vaccine in adults 18 years and older.

Similar effects were seen both with and without an SGLT2 inhibitor, according to investigators.

Margetuximab-cmkb (Margenza) was approved in December 2020 in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have previously received 2 or more anti-HER2 regimens, at least one of which for metastatic disease.

Pharmacy Times spoke with Bhavesh Shah, associate chief pharmacy officer for hematology/oncology, about his session titled Stand Strong Against Platelet Destruction With Tavalisse®: A Patient’s ITP Treatment Journey, which he presented at the 2021 ATOPP Summit.

The risk for developing the rare neurological condition are low following vaccination, with the FDA noting the benefits of vaccination far outweigh the potential risks.

The approval marks the first nonsteroidal mineralocorticoid receptor antagonist proven to significantly slow chronic kidney disease progression and reduce cardiovascular risk in individuals with chronic kidney disease associated with type 2 diabetes.

Results from the APOLLO trial showed a significant 37% reduction in the risk of progression or death, compared to pomalidomide and dexamethasone alone in patients with multiple myeloma.

Education and preparedness are essential for the treatment of this inherited disorder related to the musculosketal system.

Nivolumab (Opdivo; Bristol Myers Squibb) is FDA approved for 11 cancer indications, with the most recent approval for use in combination with certain chemotherapy for the initial treatment of gastric cancer.

The FDA also granted Breakthrough Therapy Designation to tezepelumab for patients with severe asthma without an eosinophilic phenotype in September 2018.

This action follows a recently completed phase 2a clinical trial, which demonstrated that 100% of the 10 enrolled patients met the study's primary and secondary efficacy endpoints of clinical cure at end of treatment as well as sustained clinical cure with no recurrence of CDI when examined on a 28-day follow-up visit.

According to the investigators, gene changes unique among individuals who responded to mirikizumab indicate that mirikizumab affects a distinct molecular healing pathway when compared to the spontaneous healing that occurred among the cohort administered the placebo.

No significant differences were found in blood pressure, blood sugar levels, or kidney function when comparing both medications among patients with type 2 diabetes.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

Researchers hypothesized that people may look for the UV-B type of UV light because they are unaware of their need for endorphins.

There seems to be a growing divergence of messages in the marketplace on how the pharmacy benefit is valued.

Mary Reed, DrPH, research scientist at Kaiser Permanente, discussed the changes made to health care practices in light of the COVID-19 pandemic that she would like to see remain in place in the future.